Advances in nanoparticle, liposomal, and hydrogel-based formulations now enable targeted or sustained delivery of MMP-9 modulators—ranging from tetracyclines and TIMP-mimetics to small-molecule zinc chelators—directly to inflamed, fibrotic, or tumor tissues while minimizing systemic toxicity. This evidence concerns the gene TIMP1 and neoplasm.